Although SGLT2 is rarely present in cardiomyocytes, acute systemic administration of dapagliflozin prior to ischemia significantly suppressed myocardial myoglobin efflux during myocardial I/R possibly due to a systemic effect. This evidence concerns the gene SLC5A2 and ischemia.